A Study of LY2409021 in Patients With Type 2 Diabetes

Inclusion Criteria

• Have a diagnosis of Type 2 diabetes mellitus according to the World Health Organization (WHO) diagnostic criteria
• Are women not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause.
• Are male patients using a reliable method of birth control during the study and until 3 months after the last dose of study medication.
• Are being treated with either diet and exercise alone, or with diet and exercise in combination with metformin. Metformin therapy must have been stable and unchanged for at least 3 months prior to screening and at a dose of at least 1000 milligram per day (mg/day).
• Have a hemoglobin A1c (HbA1c) value of 7.0% to 10.5%, inclusive.
• Have a body mass index (BMI) between 25 to 45 kilogram per meter squared (kg/m^2), inclusive.

In the opinion of the investigator, are capable and willing to:

• Perform self-monitoring of blood glucose
• Complete a study diary as required for this protocol
• Maintain consistent dietary, physical activity, and sleeping patterns throughout the duration of the study
• Comply with treatment regimens
• Have given written informed consent to participate in this study in accordance with local regulations and the Ethical Review Board (ERB) governing the study site.

Exclusion Criteria

• Have more than 1 episode of severe hypoglycemia (defined as an event during which the patient requires the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) within 6 months prior to screening, or have a current diagnosis of hypoglycemia unawareness.
• Have had two or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening.
• Have gastrointestinal disease that may significantly impact gastric emptying or motility or have undergone gastric bypass or gastric banding surgery.
• Have had a previous diagnosis of pancreatitis.
• Have New York Heart Association (NYHA) class II, III, or IV symptoms of heart failure
• Have a history of myocardial infarction, unstable angina, or a coronary revascularization procedure within 6 months of screening.
• Have a history of supraventricular tachycardia, ventricular tachycardia, or other cardiac arrhythmia.
• Have a history of transient ischemic attack (TIA) or stroke within 6 months of screening.
• Have poorly controlled hypertension (systolic blood pressure greater than or equal to 150 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg) as determined by the mean of three separate measurements.
• Show evidence of labile blood pressure, including symptomatic postural hypotension.
• Have any abnormality of the ECG that would impact patient safety or data interpretation.
• Show clinical signs or symptoms of liver disease, or liver function tests (LFTs; aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than 2.5 times upper limit of normal (ULN) as determined by the central laboratory at screening.
• Have a current or previous diagnosis of Gilbert's disease.
• Have previous or current diagnosis of Hepatitis B or C
• Have a serum creatinine >2 milligrams per deciliter (mg/dL) or, in patients being treated with metformin, a serum creatinine above (or creatinine clearance below) what is approved in the metformin product labeling in the respective country.
• Show evidence of uncorrected hypothyroidism or hyperthyroidism based on clinical evaluation and/or an abnormal thyroid stimulating hormone result as determined by the central laboratory at screening; patients receiving dose-stable thyroid replacement therapy for at least 3 months prior to screening will be allowed to participate in the study.
• Have any other abnormal laboratory value that, in the opinion of the investigator, precludes the patient from participation in the study. Laboratory abnormalities consistent with type 2 diabetes mellitus and all other eligibility criteri